Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories diagnostics Segment Total — Worldwide Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
8,937
Period ended Dec 31, 2025
Change on a year earlier
-4.3%
9,341 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diagnostics Segment Total — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8,937 | -4.3% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 9,341 | -6.5% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 9,988 | -39.4% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 16,469 | +5.3% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 15,644 | +44.8% | SEC Filing (0001628280-23-001516) ↗ |
| FY2020 | Dec 31, 2020 | 10,805 | +40.1% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 7,713 | +2.9% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 7,495 | +33.5% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 5,616 | +16.7% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 4,813 | +3.6% | SEC Filing (0001104659-17-003920) ↗ |
| FY2015 | Dec 31, 2015 | 4,646 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up diagnostics segment total — worldwide revenue ($m)
- Diagnostics Segment Total — Organic / Comparable Sales Growth (%)-4.5% · FY2025
- Diagnostics Segment Total — Reported Sales Growth (%)-4.3% · FY2025
- Diagnostics Segment Total — Foreign Exchange Impact on Sales Growth (%)0.2% · FY2025
- Diagnostics Segment Total — U.S. Revenue ($M)3,535 · FY2025
- Diagnostics Segment Total — International Revenue ($M)5,402 · FY2025
- Diagnostics — Annual Volume Growth (%)-2.4% · FY2025
- Diagnostics — Annual Net Selling Price Change (%)-2.1% · FY2025
- Diagnostics — Annual Foreign Exchange Impact (%)0.2% · FY2025
- Diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M)6,100 · FY2025
- Diagnostics — Global Manufacturing Facilities (Sites)21 · FY2025
- Diagnostics — Segment Research & Development Expense ($M)602 · FY2025
- Diagnostics — Segment Property & Equipment Additions ($M)761 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Diagnostics Segment Total — Worldwide Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-tot-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.